SIRI (Systemic Inflammation Response Index): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

The Systemic Inflammation Response Index (SIRI) is a novel, integrated inflammatory biomarker derived from the complete blood count with differential. It is calculated as:

SIRI = (Neutrophil count × Monocyte count) ÷ Lymphocyte count

SIRI uniquely captures the interplay between three key myeloid and lymphoid lineages:

· Neutrophils – first‑line innate immune effectors, drivers of acute and chronic inflammation, mediators of tissue damage.

· Monocytes – precursors to macrophages and dendritic cells; they orchestrate antigen presentation, cytokine production, and chronic inflammatory responses. Monocytosis is a hallmark of persistent inflammation, malignancy, and autoimmune disease.

· Lymphocytes – regulators of adaptive immunity and immunological memory; lymphopenia signals physiological stress, immunosuppression, or immune exhaustion.

By combining these three parameters, SIRI provides a comprehensive assessment of the innate‑adaptive immune balance, with particular emphasis on monocyte‑driven chronic inflammation. An elevated SIRI indicates a state of myeloid‑dominant inflammation: increased neutrophil and monocyte activity coupled with relative lymphopenia (adaptive immune suppression).

Clinical utility: SIRI is not a diagnostic test but a powerful prognostic and risk‑stratification tool. It was originally developed and validated in pancreatic cancer, but has since been extensively studied across:

· Oncology: Pre‑treatment SIRI independently predicts poorer survival in pancreatic, gastric, colorectal, hepatocellular, lung, breast, ovarian, and renal cell carcinomas, as well as haematological malignancies. It consistently outperforms NLR and PLR in many solid tumour models.

· Cardiovascular disease: SIRI predicts major adverse cardiac events, mortality after myocardial infarction, stroke severity, and outcomes in heart failure and peripheral artery disease.

· Infectious diseases: SIRI correlates with severity in sepsis, COVID‑19, pneumonia, and tuberculosis.

· Autoimmune / inflammatory disorders: SIRI reflects disease activity in rheumatoid arthritis, lupus, inflammatory bowel disease, and vasculitis.

· Critical care: SIRI at admission predicts mortality in intensive care unit patients.

SIRI is inexpensive, universally available from routine complete blood counts, and can be trended serially. As with all inflammatory markers, it must be interpreted within the clinical context.

---

2. What does it measure

a. Units of measurement

· Dimensionless ratio – calculated as:

· SIRI = (Neutrophil count × Monocyte count) ÷ Lymphocyte count

· All three counts are expressed in the same units (×10⁹/L or /μL), rendering the index unit‑free.

b. Normal Range and Optimal Targets

(Reference intervals vary by age, sex, ethnicity, and laboratory; the following are derived from large population studies and prognostic cut‑points. There is no universal consensus; the values below represent commonly cited thresholds.)

Adults:

· Optimal / low risk: SIRI less than 1.0

· Normal / acceptable: SIRI 1.0–1.5

· Borderline elevated: SIRI 1.5–2.0

· Elevated / adverse prognosis: SIRI 2.0–3.0

· Severely elevated / high risk: SIRI greater than 3.0

Children:

· Normal ranges are age‑dependent; infants have higher lymphocyte counts and lower neutrophil/monocyte counts, resulting in lower SIRI.

· Infants and toddlers: often 0.3–0.8

· Older children: progressively approach adult ranges by adolescence.

· Use age‑matched reference ranges from the reporting laboratory.

Elderly:

· Mild age‑related increase in SIRI due to immunosenescence (lymphopenia) and increased inflammatory stimuli.

Interpretation notes:

· SIRI is a continuous variable; optimal cut‑offs vary by disease and outcome. Oncology studies often use thresholds of 1.2–1.8; cardiovascular studies range from 1.0–1.5.

· Isolated elevated SIRI with normal individual cell counts should prompt repeat testing; occult infection, inflammation, or early malignancy may cause subtle elevation.

· Very low SIRI (<0.5) is uncommon in adults and may indicate pancytopenia (bone marrow failure), severe malnutrition, or advanced liver disease; investigate if persistent.

· Always examine the absolute neutrophil, monocyte, and lymphocyte counts – the index alone does not reveal which lineage(s) are deranged.

· SIRI is particularly sensitive to monocyte elevation, which distinguishes it from NLR and makes it a superior marker for chronic inflammatory states and certain malignancies.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise SIRI)

SIRI is increased by neutrophilia, monocytosis, lymphopenia, or any combination thereof.

Factors that cause neutrophilia (↑ neutrophils):

· Acute inflammation / infection: bacterial infections, sepsis, abscess, pneumonia, pyelonephritis, appendicitis.

· Tissue injury / necrosis: surgery, trauma, burns, myocardial infarction, pancreatitis, fracture.

· Chronic inflammation: rheumatoid arthritis, gout, vasculitis, inflammatory bowel disease.

· Malignancy: solid tumours (paraneoplastic neutrophilia), myeloproliferative neoplasms, chronic myeloid leukaemia.

· Medications: corticosteroids, lithium, beta‑agonists, granulocyte colony‑stimulating factor (G‑CSF).

· Metabolic: diabetic ketoacidosis, uraemia, eclampsia.

· Physiological: pregnancy (third trimester), exercise, stress, smoking.

Factors that cause monocytosis (↑ monocytes):

· Chronic inflammation / autoimmune disease: rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, sarcoidosis.

· Chronic infections: tuberculosis, fungal infections (histoplasmosis, coccidioidomycosis), brucellosis, syphilis, protozoal (leishmaniasis, malaria).

· Malignancy:

· Solid tumours: paraneoplastic monocytosis (pancreatic, ovarian, gastric, colorectal).

· Haematological: acute myeloid leukaemia (monocytic subtypes – M4, M5), chronic myelomonocytic leukaemia (CMML), juvenile myelomonocytic leukaemia, Hodgkin and non‑Hodgkin lymphoma.

· Haematological disorders: myeloproliferative neoplasms, haemolytic anaemia, immune thrombocytopenia, post‑splenectomy.

· Recovery phase of bone marrow suppression: rebound monocytosis after chemotherapy.

· Medications: granulocyte colony‑stimulating factor (G‑CSF), some antipsychotics.

· Other: obesity, smoking, stress.

Factors that cause lymphopenia (↓ lymphocytes):

· Acute stress / critical illness: trauma, surgery, myocardial infarction, sepsis – cortisol‑mediated.

· Infections: viral (HIV, influenza, COVID‑19, hepatitis), bacterial sepsis, tuberculosis.

· Immunosuppressive therapy: corticosteroids, chemotherapy, radiation, calcineurin inhibitors, mycophenolate.

· Autoimmune diseases: SLE, rheumatoid arthritis, sarcoidosis.

· Malnutrition / protein‑energy wasting: alcoholism, anorexia nervosa.

· Genetic: DiGeorge syndrome, severe combined immunodeficiency (SCID).

· Haematological: aplastic anaemia, advanced lymphoma, leukaemia.

· Ageing: physiological decline in T‑cell production.

Thus, elevated SIRI is associated with:

· Chronic inflammatory and autoimmune diseases (particularly those with monocyte involvement).

· Solid organ and haematological malignancies (especially those with monocytic differentiation or paraneoplastic monocytosis).

· Chronic infections (tuberculosis, fungal, parasitic).

· Acute inflammation and tissue injury (where neutrophilia predominates).

· Physiological stress, immunosuppression, and malnutrition.

· Post‑splenectomy state.

b. Indirect correlation (factors that influence SIRI interpretation or cause artefactual changes)

· Circadian rhythm: Neutrophil, monocyte, and lymphocyte counts exhibit diurnal variation. For serial comparisons, collect blood at a consistent time (morning fasting is preferred).

· Exercise: Intense acute exercise causes transient neutrophilia, monocytosis, and lymphocytosis, followed by delayed lymphopenia. Defer testing for 24–48 hours after strenuous exertion.

· Pregnancy: Neutrophils rise; monocytes may increase; lymphocytes decline. SIRI increases physiologically in the third trimester. Not a reliable marker during pregnancy; use non‑pregnant reference ranges only after 6 weeks postpartum.

· Smoking: Chronic smokers have elevated neutrophils and monocytes, and often lower lymphocytes; SIRI is chronically elevated.

· Alcohol: Chronic alcoholism causes monocytosis (due to liver inflammation) and lymphopenia; SIRI is often elevated.

· Medications:

· Increase SIRI: corticosteroids, G‑CSF, lithium, epinephrine.

· Decrease SIRI: chemotherapy (may cause pancytopenia), immunosuppressants (azathioprine, mycophenolate – may lower neutrophils and monocytes).

· Splenectomy: Monocytosis without significant changes in neutrophils/lymphocytes → SIRI increases.

· Ethnicity: African and Afro‑Caribbean populations have physiologically lower neutrophil counts (benign ethnic neutropenia). SIRI may be lower for the same inflammatory stimulus; reference ranges should ideally be stratified.

· Assay variability: Automated haematology analysers may misclassify blasts, immature granulocytes, or atypical monocytes; manual differential is gold standard when monocytosis or abnormal flags are present.

---

4. Disorders related to abnormal values

a. When SIRI is elevated (clinically significant – adverse prognostic marker)

Oncology:

· Pancreatic ductal adenocarcinoma: SIRI was originally validated in pancreatic cancer. Pre‑treatment SIRI >1.2–1.8 independently predicts poorer overall survival, disease‑free survival, and resectability. Elevated SIRI correlates with advanced stage, lymph node metastasis, and cachexia.

· Gastric cancer: Pre‑operative SIRI >1.0–1.5 predicts poor prognosis, peritoneal metastasis, and recurrence after curative resection.

· Colorectal cancer: SIRI >1.5–2.0 is independently associated with shorter survival and higher recurrence rates; outperforms NLR and PLR in some cohorts.

· Hepatocellular carcinoma: SIRI >1.5 predicts aggressive tumour biology, vascular invasion, and poor response to locoregional therapy.

· Lung cancer: Both non‑small cell and small cell lung cancer; elevated SIRI correlates with advanced stage, metastases, and inferior outcomes.

· Breast cancer: SIRI >1.2 is associated with triple‑negative subtype, higher tumour grade, and reduced survival.

· Ovarian cancer: Pre‑treatment SIRI >1.8 predicts platinum resistance and poorer progression‑free survival.

· Renal cell carcinoma: SIRI >1.5 is an independent prognostic factor for overall survival.

· Haematological malignancies:

· Acute myeloid leukaemia (monocytic subtypes M4/M5): Elevated SIRI at diagnosis reflects high leukaemic burden and predicts lower remission rates.

· Chronic myelomonocytic leukaemia (CMML): SIRI is intrinsically elevated due to monocytosis; correlates with disease severity and progression to acute leukaemia.

· Lymphoma: Elevated SIRI predicts aggressive disease and poorer response to therapy.

Cardiovascular disease:

· Acute coronary syndrome / myocardial infarction: Elevated SIRI at presentation independently predicts in‑hospital mortality, heart failure, recurrent ischaemia, and long‑term major adverse cardiac events.

· Ischaemic stroke: SIRI correlates with infarct volume, haemorrhagic transformation, early neurological deterioration, and 90‑day mortality.

· Heart failure: SIRI predicts hospitalisation, cardiovascular death, and all‑cause mortality.

· Peripheral arterial disease: SIRI associates with disease severity, critical limb ischaemia, and amputation risk.

Infectious diseases:

· Sepsis / bacteraemia: SIRI >2.5–3.0 strongly suggests bacterial infection and predicts progression to septic shock, acute respiratory distress syndrome, and death.

· COVID‑19: SIRI >1.5–2.0 at admission identifies patients at high risk of severe disease, intensive care admission, invasive mechanical ventilation, and mortality. SIRI declines with recovery.

· Tuberculosis: SIRI correlates with disease extent, cavitation, and delayed sputum conversion.

· Fungal infections: Particularly in immunocompromised hosts; monocytosis and neutrophilia elevate SIRI.

Autoimmune / inflammatory diseases:

· Rheumatoid arthritis: SIRI correlates with DAS28 score, acute phase reactants, and radiographic progression; normalises with successful immunosuppression.

· Systemic lupus erythematosus: SIRI reflects disease activity and predicts flares.

· Inflammatory bowel disease: SIRI correlates with endoscopic activity and CRP; distinguishes active from quiescent disease.

· Sarcoidosis: SIRI associates with progressive pulmonary disease and extrapulmonary involvement.

· Vasculitis: Elevated SIRI at diagnosis predicts relapses and poor response to therapy.

Chronic kidney disease:

· SIRI predicts cardiovascular events, progression to end‑stage renal disease, and all‑cause mortality independent of eGFR.

Obesity and metabolic syndrome:

· Chronic low‑grade inflammation with monocytosis elevates SIRI; correlates with insulin resistance and NAFLD.

Post‑splenectomy:

· Reactive monocytosis elevates SIRI; benign finding but must be distinguished from CMML.

b. When SIRI is low (usually favourable, but context‑dependent)

· Generally desirable: low SIRI indicates balanced myeloid and lymphoid populations, low inflammatory activity.

· Physiological: children, healthy adults with regular exercise, non‑smokers, no acute or chronic illness.

· Pancytopenia: bone marrow failure (aplastic anaemia), chemotherapy, myelodysplastic syndromes, advanced liver disease with hypersplenism – SIRI may be very low, but this confers infection and bleeding risk.

· Severe malnutrition / cachexia: protein‑energy wasting leads to lymphopenia and sometimes neutropenia/monocytopenia; SIRI may be low, reflecting immune exhaustion.

· HIV with advanced immunodeficiency: lymphopenia may be profound; however, chronic immune activation often elevates monocytes, making SIRI variable.

Interpretation note: An isolated low SIRI in an otherwise healthy, asymptomatic individual with normal absolute cell counts is not a cause for concern and does not require investigation.

---

5. Best way to address aberrant levels

Important principle: SIRI is a marker, not a disease. There is no treatment to directly normalise SIRI. Intervention must target the underlying condition causing neutrophilia, monocytosis, or lymphopenia. Normalising SIRI is a sign that the underlying disease is controlled, inflammation is subsiding, nutritional status is improving, or the offending medication has been adjusted.

a. Quick ways or using Medications

There is no medication approved specifically to lower SIRI. The following interventions address the underlying causes:

For neutrophilia:

· Treat infection: appropriate antimicrobial, antiviral, or antifungal therapy.

· Control inflammation: disease‑modifying antirheumatic drugs (DMARDs), biologics, corticosteroids for autoimmune flares.

· Treat malignancy: surgery, chemotherapy, radiotherapy, targeted therapy.

· Remove causative medication: if drug‑induced (corticosteroids, lithium, G‑CSF), taper or switch if clinically feasible.

· Manage metabolic causes: insulin for diabetic ketoacidosis, dialysis for uraemia.

For monocytosis:

· Treat underlying inflammatory or infectious disease:

· Autoimmune disease: DMARDs, biologics, corticosteroids.

· Chronic infection: appropriate antimicrobial therapy (tuberculosis, fungal).

· Treat malignancy:

· Solid tumours: surgical resection, chemotherapy, immunotherapy.

· Haematological malignancies:

· CMML: cytoreductive therapy (hydroxyurea), hypomethylating agents (azacitidine, decitabine), targeted therapy (ruxolitinib), allogeneic stem cell transplant in eligible patients.

· AML (monocytic subtypes): induction chemotherapy, targeted therapy.

· Splenectomy‑induced monocytosis: no treatment required; benign.

For lymphopenia:

· Treat underlying infection: antiretroviral therapy for HIV, antiviral agents.

· Reduce immunosuppression: taper corticosteroids when possible, switch to less lymphotoxic agents.

· Nutritional repletion: correct deficiencies of protein, zinc, vitamin B12, folate.

· Treat autoimmune disease: immunosuppressive therapy may cause lymphopenia; balance disease control against lymphocyte preservation.

For acute stress / critical illness:

· Haemodynamic stabilisation: fluids, vasopressors, source control.

· Supportive care: adequate oxygenation, nutrition, glycaemic control.

Do not self‑prescribe – all prescription medications require medical supervision.

b. Using Supplements or Holistic medicine

Supplements with evidence for supporting immune balance and reducing inflammatory drivers of SIRI – as adjuncts to definitive therapy:

For reducing neutrophilic and monocytic inflammation:

· Omega‑3 fatty acids (EPA/DHA):

· Reduce neutrophil chemotaxis and oxidative burst; inhibit monocyte activation and pro‑inflammatory cytokine production.

· Preferred source: Algae oil – sustainable, plant‑based, direct EPA/DHA, no marine contaminants.

· Avoid conventional fish oil (overfishing, ocean pollution, ethical concerns).

· Dose: 2–4 g/day EPA/DHA for anti‑inflammatory effect.

· Curcumin (turmeric):

· Anti‑inflammatory; inhibits NF‑κB, reducing neutrophil and monocyte activation.

· Suppresses monocyte recruitment and macrophage polarisation toward pro‑inflammatory M1 phenotype.

· Use phytosomal, liposomal, or with piperine for bioavailability.

· Avoid products with added synthetic folic acid or cyanocobalamin.

· Green tea catechins (EGCG):

· Anti‑inflammatory; inhibits neutrophil and monocyte chemotaxis.

· Use beverage (2–3 cups/day) rather than concentrated extracts (hepatotoxicity risk).

· Boswellia serrata (frankincense):

· Contains boswellic acids; anti‑inflammatory, inhibits 5‑lipoxygenase.

· May reduce monocyte‑mediated inflammation in autoimmune disease.

· Preferred source: standardised extract with ≥30% boswellic acids.

· Ginger (Zingiber officinale):

· Anti‑inflammatory; inhibits neutrophil degranulation and monocyte cytokine production.

· Use fresh or powdered; standardised extracts available.

· Resveratrol:

· Polyphenol; inhibits monocyte activation and adhesion molecule expression.

· Found in red grapes, berries, peanuts; supplementation available but evidence modest.

· Vitamin D:

· Deficiency associated with immune dysregulation and monocyte activation.

· Supplementation reduces inflammatory monocyte subsets.

· Preferred: D3 (cholecalciferol) from lichen.

· Dose: 600–2000 IU/day for maintenance; higher doses for deficiency correction (under guidance).

For supporting lymphocyte recovery and reducing lymphopenia:

· Zinc:

· Essential for T‑cell development and function; deficiency causes lymphopenia.

· Supplementation in deficient individuals increases lymphocyte counts and improves SIRI.

· Preferred form: zinc picolinate or zinc citrate.

· Dose: 15–30 mg elemental zinc/day; monitor copper with long‑term use.

· Vitamin B12 and folate:

· Deficiency causes ineffective haematopoiesis, including lymphopenia.

· Use methylcobalamin and methylfolate – active forms, avoid synthetic folic acid and cyanocobalamin.

· Dose: methylcobalamin 1000–2000 mcg/day, methylfolate 400–1000 mcg/day if deficient.

· Selenium:

· Co‑factor for antioxidant enzymes; deficiency impairs lymphocyte proliferation.

· Supplementation in deficient individuals may improve immune function.

· Ashwagandha (Withania somnifera):

· Adaptogen; may reduce stress‑induced lymphopenia.

· Limited evidence; use standardised extracts from GMP‑certified manufacturers.

· Reishi mushroom (Ganoderma lucidum):

· Beta‑glucans; immunomodulatory, may enhance lymphocyte activity.

· Preferred source: fruiting body extract, certified organic.

Supplements with broad anti‑inflammatory effects that may lower SIRI:

· Vitamin C:

· Antioxidant; reduces oxidative stress and may modulate neutrophil and monocyte function.

· High‑dose intravenous vitamin C used experimentally in sepsis and cancer; oral supplementation for SIRI improvement lacks robust evidence.

· Probiotics / prebiotics:

· Modulate gut microbiota; emerging evidence suggests they reduce systemic inflammation and may improve immune balance.

· Preferred sources: fermented plant foods (kimchi, sauerkraut, kombucha, miso, tempeh); standardised probiotic supplements with documented strains.

Supplements to avoid:

· Products with added synthetic folic acid or cyanocobalamin – use methylfolate and methylcobalamin if needed.

· Unregulated herbal blends with undisclosed ingredients.

· High‑dose vitamin E – may impair immune function.

· High‑dose iron without confirmed deficiency – causes oxidative stress.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

Diet is a cornerstone of systemic inflammation control and immune homeostasis. A well‑designed, nutrient‑dense plant‑based diet supports lymphocyte function, modulates neutrophil and monocyte activity, and promotes a favourable SIRI.

Core dietary principles – what to emphasise:

· Anti‑inflammatory dietary pattern:

· Mediterranean‑style plant‑forward diet – abundant vegetables, fruits, legumes, whole grains, nuts, seeds, olive oil.

· High in polyphenols, fibre, unsaturated fats, and antioxidants.

· Low in refined carbohydrates, added sugars, and saturated fats.

· Consistently associated with lower inflammatory markers (CRP, IL‑6) and reduced monocyte activation.

· Adequate protein intake:

· Essential for lymphocyte synthesis and immune competence.

· Plant‑based protein sources (hierarchy adhered):

· Primary: legumes (lentils, chickpeas, beans, soy products – tofu, tempeh, edamame).

· Fungi / algae: mycoprotein (Quorn), spirulina, chlorella.

· Biotechnology: precision‑fermented dairy proteins (animal‑free whey, casein) – acceptable emerging options.

· Dairy / eggs: permitted but not emphasised; low‑fat fermented dairy (yoghurt, kefir) if tolerated.

· Meat, poultry, fish: deliberately omitted. Effective plant‑based alternatives exist to meet all protein requirements for immune health.

· Zinc‑rich plant foods:

· Pumpkin seeds, hemp seeds, chickpeas, lentils, cashews, quinoa.

· Soaking and sprouting legumes and seeds reduces phytate and enhances zinc absorption.

· Vitamin B12:

· No reliable plant‑based whole food source. Must be supplemented or obtained from fortified foods (plant milks, nutritional yeast with methylcobalamin).

· Precision‑fermented B12 – ecologically responsible, non‑animal, preferred.

· Folate:

· Abundant in leafy greens, legumes, asparagus, beets, sunflower seeds.

· Deficiency impairs lymphocyte proliferation.

· Vitamin C‑rich foods:

· Citrus fruits, guava, bell peppers, broccoli, kiwi, strawberries, amla (Indian gooseberry).

· Vitamin D:

· Sunlight exposure primary; fortified plant milks; supplement from lichen if needed.

· Selenium:

· Brazil nuts (1–2 per day), sunflower seeds, mushrooms, whole grains.

· Omega‑3 fatty acids:

· ALA sources: ground flaxseeds, chia seeds, hemp seeds, walnuts.

· Direct EPA/DHA: microalgae (spirulina, chlorella – limited amounts); algae oil supplements for therapeutic doses.

· Polyphenol‑rich foods:

· Berries (blueberries, strawberries, blackberries, raspberries) – anthocyanins.

· Green tea – catechins.

· Dark chocolate (≥70% cocoa) – flavonoids.

· Extra virgin olive oil – oleocanthal.

· Turmeric, ginger – fresh or powdered.

· Cruciferous vegetables (broccoli, kale, Brussels sprouts, cabbage) – sulforaphane.

· Onions, garlic, leeks – quercetin, organosulfur compounds.

· Citrus fruits – naringenin, hesperidin.

· Apples, grapes – flavonoids.

· Fermented plant foods:

· Kimchi, sauerkraut, kombucha, miso, tempeh – support gut microbiome diversity and reduce systemic inflammation.

· Mushrooms:

· Shiitake, maitake, oyster, reishi – beta‑glucans and ergothioneine; immunomodulatory, may reduce monocyte activation.

What to avoid or severely limit:

· Ultra‑processed foods, refined carbohydrates, added sugars – promote inflammation, insulin resistance, and dyslipidaemia; increase neutrophil and monocyte counts.

· Excess alcohol – causes monocytosis (via liver inflammation) and lymphopenia; abstinence recommended if SIRI is persistently elevated.

· Trans fats – partially hydrogenated oils; pro‑inflammatory.

· Saturated fats – excess intake may promote monocyte activation and inflammation.

· Red and processed meats – associated with systemic inflammation and iron overload; not required.

· Smoking – single most important modifiable risk factor for elevated SIRI (increases neutrophils, monocytes, decreases lymphocytes); cessation improves all three lineages.

Lifestyle factors with proven benefit for SIRI:

· Regular moderate aerobic exercise: 30–60 minutes, most days – reduces resting neutrophil and monocyte counts, enhances lymphocyte circulation, and lowers SIRI.

· High‑intensity interval training (HIIT): may be even more effective for improving inflammatory profiles.

· Stress reduction: chronic stress elevates cortisol, causing neutrophilia, monocytosis, and lymphopenia; mindfulness, meditation, yoga, deep breathing, adequate sleep (7–9 hours).

· Smoking cessation: SIRI begins to decrease within 2–4 weeks; maximal effect at 3–6 months.

· Weight loss: in overweight/obese individuals, 5–10% weight loss reduces systemic inflammation, lowers monocyte counts, and improves SIRI.

· Alcohol moderation / abstinence: as above.

---

6. How soon can one expect improvement and the ideal time frame to retest

SIRI is moderately dynamic; response time depends entirely on the underlying cause and intervention.

For acute neutrophilia / monocytosis (infection, inflammation):

· Antibiotics / anti‑inflammatory therapy: Neutrophils begin to fall within 24–48 hours; normalisation in 3–7 days. Monocytes decline more slowly, over 1–3 weeks. SIRI improves over 1–4 weeks.

· Repeat testing: at 1–2 weeks after clinical resolution.

For chronic inflammatory / autoimmune disease:

· DMARDs / biologics / corticosteroids: Neutrophil and monocyte counts decrease over 2–4 weeks; lymphocyte recovery may take 4–12 weeks. SIRI improvement detectable at 4–8 weeks; maximal effect at 3–6 months.

· Repeat testing: every 4–8 weeks during dose titration; every 3–6 months in stable disease.

For monocytosis due to CMML or other haematological malignancy:

· Cytoreductive therapy (hydroxyurea, azacitidine): Monocyte reduction detectable in 2–4 weeks; maximal effect at 6–12 weeks.

· Repeat testing: as directed by haematologist; typically every 1–3 months.

For lymphopenia:

· Nutritional repletion (zinc, B12, folate, vitamin D): Lymphocyte counts increase within 2–4 weeks; SIRI improves over 4–8 weeks.

· Reduction of immunosuppression: lymphocyte recovery over 4–12 weeks.

· HIV antiretroviral therapy: CD4 recovery is slow; SIRI improves over 3–6 months.

· Repeat testing: at 2–3 months for nutritional intervention; at 3–6 months for HIV/immunosuppression.

For lifestyle interventions:

· Smoking cessation: SIRI begins to decrease within 2–4 weeks; maximal effect at 3–6 months.

· Weight loss / exercise: SIRI improvement detectable in 3–6 months with sustained lifestyle change.

· Alcohol abstinence: SIRI normalises over 4–8 weeks.

Retesting interval summary:

· Acute infection / inflammation: repeat at 1–2 weeks after clinical resolution.

· Chronic inflammatory / autoimmune disease on treatment: every 3–6 months.

· Haematological malignancy (CMML, AML): as directed by haematologist; typically every 1–3 months.

· Lymphopenia due to nutritional deficiency: repeat at 2–3 months.

· Lifestyle modification: repeat at 3–6 months.

· Routine health screen: every 1–2 years in stable, healthy individuals.

Do not retest SIRI more often than every 4 weeks in chronic stable conditions; in acute illness, serial monitoring may be warranted every 48–72 hours until trending downward.

---

Conclusion

The Systemic Inflammation Response Index listens to three myeloid and lymphoid voices: the neutrophil, first responder to acute injury; the monocyte, chronicler of persistent inflammation; and the lymphocyte, guardian of adaptive immunity. An elevated SIRI speaks of a system tilted toward innate, myeloid‑driven inflammation at the expense of adaptive immune competence.

This index does not diagnose; it stratifies. It tells the oncologist that the pancreatic tumour has awakened a systemic monocytic response. It tells the rheumatologist that the lupus flare is not merely serological but cellular. It tells the cardiologist that the myocardial infarction is accompanied by a persistent inflammatory signature. It tells the haematologist that monocytosis is not reactive but neoplastic.

There is no direct antagonist to SIRI. The index falls only when the root cause is addressed – the autoimmune disease suppressed, the chronic infection eradicated, the myeloproliferative neoplasm controlled, the cigarette extinguished, the weight reduced, the nutritional deficiency corrected.

A plant‑based, ecologically responsible diet – rich in legumes, whole grains, nuts, seeds, mushrooms, and algae‑derived omega‑3s – provides the nutritional foundation for immune homeostasis. It supplies the zinc, folate, B12, and protein required for lymphocyte competence; its polyphenols and fibre dampen neutrophil and monocyte activation; it corrects deficiencies without the pro‑inflammatory and ecological cost of animal products. Meat is not merely unnecessary; its displacement by plants is itself an anti‑monocytic, immune‑restorative intervention.

SIRI is a number. It is also a narrative of myeloid inflammation and lymphoid exhaustion, of chronic disease burden and therapeutic response. Learn to read it – and then learn to act.

---x-x-

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x-